PedAM
Pediatric Disease Annotations & Medicines
| Disease | liver disease |
| Symptom | |liver fibrosis |
| Sentences | 87 |
| PubMedID- 24524002 | Evaluation of liver fibrosis in patients with chronic liver disease is crucial for understanding the disease state, predicting prognosis and selecting the appropriate treatment. |
| PubMedID- 21039833 | In clinical practice, it is important to assess the severity of liver fibrosis in patients with various liver diseases to determine the prognosis, decide treatment, and monitor disease progression and response to treatment. |
| PubMedID- 24274743 | By this modification, the authors demonstrated that the processes occur in the natural course of human liver disease––chronic hepatitis leading to liver fibrosis as the basis of liver cancer–could be even more closely mimicked. |
| PubMedID- 23954132 | liver fibrosis is a consequence of chronic liver diseases and thus a major cause of mortality and morbidity. |
| PubMedID- 22140659 | Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease. |
| PubMedID- 20957171 | Inflammatory processes are involved in a large number of liver diseases and may lead to liver fibrosis and cirrhosis.1 dexamethasone acetate (dxma) is a synthesized glucocorticoid, which has been used as an anti-inflammatory drug in the treatment of chronic active hepatitis for the prevention of liver fibrosis.2 although dxma enhances hepatocyte viability and improves the expression of liver-specific genes in liver diseases, the response rates obtained from a series of recent clinical trials were poor, which can be explained by the following factors. |
| PubMedID- 22087165 | Commentary on: aspartate transaminase to platelet ratio index (apri): a simple noninvasive index assessing liver fibrosis in patients with chronic liver diseases. |
| PubMedID- 23152415 | Background: serum hyaluronic acid and biochemical models which require hyaluronic acid analysis are commonly used as predictors of liver fibrosis in patients with chronic liver disease, however biological variation data for hyaluronic acid are deficient. |
| PubMedID- 25633908 | Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. |
| PubMedID- 22087183 | Aspartate transaminase to platelet ratio index (apri) to assess liver fibrosis in patients with chronic liver disease. |
| PubMedID- 22168074 | Elastography efficiency in the liver fibrosis determination in patients with nonalcoholic fatty liver disease. |
| PubMedID- 23192205 | Objective: the objective of this study was to determine whether arterial enhancement fraction (aef) is associated with the degree of liver fibrosis and cirrhosis in patients with chronic liver disease. |
| PubMedID- 20373368 | Homozygosity for the patatin-like phospholipase-3/adiponutrin i148m polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. |
| PubMedID- 26049707 | Objective: the purpose of this study was to noninvasively estimate disease activity and liver fibrosis in patients with nonalcoholic fatty liver disease (nafld) using anthropometric and biochemical characteristics and the c-methionine breath test (mebt). |
| PubMedID- 24342745 | Background & aims: series studies have associated increased serum levels of ferritin with liver fibrosis in patients with nonalcoholic fatty liver disease. |
| PubMedID- 26133817 | Conclusions: lsm is a convenient and reliable approach for diagnosis of liver fibrosis in patients with chronic liver disease. |
| PubMedID- 22087167 | Is the aspartate transaminase to platelet ratio index adequate for the assessment of liver fibrosis in patients with chronic liver disease? |
| PubMedID- 23630312 | Conclusion: arfi elastography is reliable in the assessment of liver fibrosis in patients with chronic liver disease, especially nonobese patients. |
| PubMedID- 25836944 | Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity. |
| PubMedID- 23554863 | The techniques can predict the presence of cirrhosis and related complications such as portal hypertension and both techniques have shown to be of value for the non-invasive detection of liver fibrosis in patients with chronic liver disease , . |
| PubMedID- 26122378 | Chronic liver disease commonly leads to liver fibrosis, resulting in development of liver cirrhosis, organ failure, and eventually liver related mortality. |
| PubMedID- 22609320 | We assessed the performance of ultrasound elastography using real-time acoustic radiation force imaging (arfi) technology in evaluating the degree of liver fibrosis in children with and without liver disease. |
| PubMedID- 25173375 | liver fibrosis is the result of chronic liver disease, which is caused by sustaining multiple damage or injury to the liver. |
| PubMedID- 25496860 | Comparative study of transient elastography versus real-time tissue elastography for assessment of liver fibrosis in patients with chronic liver disease. |
| PubMedID- 25009372 | Several noninvasive laboratory tests have been used to assess liver fibrosis in patients with alcoholic liver disease, including the hyaluronic acid, fibrotest, fibrometera, hepascore, forns and apri indexes, fib4, an algorithm combining prothrombin index (pi), alpha-2 macroglobulin and hyaluronic acid. |
| PubMedID- 22543095 | Portal hypertension is a common complication of chronic liver diseases associated with liver fibrosis and cirrhosis. |
| PubMedID- 26006229 | liver fibrosis, the main characteristic of chronic liver diseases, is strongly associated with the activation of hepatic stellate cells (hscs), which are responsible for extracellular matrix production. |
| PubMedID- 24416739 | Objective: to determine practices among physicians in canada for the assessment of liver fibrosis in patients with chronic liver diseases. |
| PubMedID- 23578751 | Background: it was recently reported that serum interleukin (il)-17 levels increased in liver fibrosis associated with human alcoholic liver disease. |
| PubMedID- 26494961 | Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. |
| PubMedID- 24670988 | The liver stiffness measurement using transient elastography (te) is a rapid, noninvasive, and reproducible method of assessing liver fibrosis in patients with chronic liver diseases such as chronic hepatitis c, chronic hepatitis b, alcoholic liver disease, and primary biliary cirrhosis . |
| PubMedID- 20526777 | Objective: transient elastography (te) has shown promising results for the staging of liver fibrosis in patients with non-alcoholic fatty liver disease (nafld) and steatohepatitis (nash) with the limitation that 25% of obese patients cannot be examined with the standard te probe. |
| PubMedID- 25038804 | According to these guidelines, us elastography is useful to assess the severity of liver fibrosis in patients with diffuse liver disease and particularly to distinguish patients with nil to mild fibrosis from those with significant fibrosis, although some of the newer techniques must be validated through clinical studies. |
| PubMedID- 26494949 | Although liver biopsy remains the reference standard for evaluating the extent of liver fibrosis in patients with chronic liver diseases, several noninvasive methods such as te and arfi have been developed as alternatives to liver biopsies. |
| PubMedID- 24552673 | In this study, our goal was to assess the performance of swe in the staging of liver fibrosis in children with chronic liver disease. |
| PubMedID- 24628717 | Clinical usage of serum ferritin to assess liver fibrosis in patients with non-alcoholic fatty liver disease: proceed with caution. |
| PubMedID- 22965536 | Liver stiffness measurement by transient elastography is a noninvasive method for assessing liver fibrosis in patients with chronic liver disease. |
Page: 1 2